Lakefront Biotherapeutics (LKFT) Liabilities and Shareholders Equity (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Liabilities and Shareholders Equity for 13 consecutive years, with $3.9 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 6.67% year-over-year to $3.9 billion; the TTM figure through Mar 2026 stood at $16.3 billion (up 23.5% YoY), while the FY2025 annual figure was $4.0 billion, down 10.27% from the prior year.
• Liabilities and Shareholders Equity held at $3.9 billion in Q1 2026 per LKFT's latest filing, from $4.0 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $5.7 billion in Q1 2022 and bottomed at $3.9 billion in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $4.6 billion across 5 years, with a median of $4.6 billion in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity dropped 18.69% — and 2023, when it slipped 2.94%.
• Lakefront Biotherapeutics' Liabilities and Shareholders Equity stood at $4.8 billion in 2022, then fell by 2.94% to $4.7 billion in 2023, then fell by 5.74% to $4.4 billion in 2024, then slipped by 10.27% to $4.0 billion in 2025, then slipped by 0.43% to $3.9 billion in 2026.
• Business Quant data shows LKFT's Liabilities and Shareholders Equity at $3.9 billion in Q1 2026, $4.0 billion in Q4 2025, and $4.1 billion in Q3 2025.